Clinical Trial Update: The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer [Phase 1, Phase 2]

View source ↗

Summary

This update reports results from a Phase 1/2 study evaluating the combination of GX-188E vaccination with pembrolizumab in HPV 16/18-positive advanced cervical …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• GX-188E vaccination (GX-188E)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Genexine, Inc. | Conditions: Cervical Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-07-30